133217-92-2

Usage

Chemical Properties

Clear Pale Yellow Oil

Uses

Intermediates in prodrug synthesis.

Upstream product

• 22128-62-7 carbonochloridic acid, chloromethyl ester 
• 109-89-7 diethylamine 

Downstream Products

• 872700-96-4 diethyl-carbamic acid 4-(3,5-bis-trifluoromethyl-phenyl)-[1,2,3]triazol-1-ylmethyl ester 
• 872700-93-1 diethyl-carbamic acid 4-(2-trifluoromethyl-phenyl)-[1,2,3]triazol-1-ylmethyl ester 
• 872700-97-5 diethyl-carbamic acid 4-(1-hydroxy-cyclohexyl)-[1,2,3]triazol-1-ylmethyl ester 
• 872700-94-2 diethyl-carbamic acid 4-(2-nitro-phenyl)-[1,2,3]triazol-1-ylmethyl ester 
• 872700-89-5 diethyl-carbamic acid 4-(4-methoxy-phenyl)-[1,2,3]triazol-1-ylmethyl ester 
• 872700-91-9 diethyl-carbamic acid 4-(4-amino-phenyl)-[1,2,3]triazol-1-ylmethyl ester 
• 872700-90-8 diethyl-carbamic acid 4-phenyl-[1,2,3]triazol-1-ylmethyl ester 

Relevant academic research and scientific papers

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

COMPOUNDS AND THERAPEUTIC USES THEREOF

The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders.

NH-1,2,3-triazoles from azidomethyl pivalate and carbamates: Base-labile N-protecting groups

NH-1,2,3-triazoles have been prepared via the copper(I)-catalyzed 1,3-dipolar cycloaddition between terminal alkynes and three N-protected organic azides, azidomethyl pivalate, azidomethyl morpholine-4-carboxylate, and azidomethyl N,N-diethylcarbarnate. T

Interleukin-4 gene expression inhibitors

This invention discloses and claims a class of indole and benzo(b)thiophene derivatives for use in treating allergy, asthma, rhinitis, dermatitis, B-cell lymphomas, tumors and diseases associated with bacterial, rhinovirus or respiratory syncytial virus (RSV) infections. The compounds of this invention are defined by the Formula (I): wherein X, Y, Z, R1, R2 and R3 are as defined in the specification; or a pharmaceutically acceptable salt thereof. In preferred embodiments of this invention it is also disclosed and claimed that the compounds of this invention are capable of modulating T helper (Th) cells, Th1/Th2, and thereby capable of inhibiting the transcription of interleukin-4 (IL-4) message, IL-4 release or IL-4 production.

α-Haloalkyl Haloformates and Related Compounds 3.1 A Facile Synthesis of Symmetrical and Unsymmetrical Ureas via Chloromethyl Carbamates

Chloromethyl carbamates were prepared by the reaction of chloromethyl chloroformates with amines and found to produce mono-, symmetrically or unsymmetrically di- and trisubstituted ureas including their N-hydroxy and N-alkoxy derivatives in moderate to good yield.

Acyloxymethyl carbonochloridates. New intermediates in prodrug synthesis

The synthesis of a number of stable acyloxymethyl carbonochloridates 7 has been accomplished in four steps from chloromethyl carbonochloridate 3. Each step has been optimized with propanoyl-oxymethyl carbonochloridate 7c as a model compound (64% overall yield). Diethyl ether-boron trifluoride catalyzes the conversion of carbonothioate 6cc to the carbonochloridate 7c by chlorination with sulfuryl chloride. Acylation of a few compounds containing hydroxy or amino groups by 7c is described.